Navigation Links
CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
Date:2/23/2010

CAMBRIDGE, England, February 23, 2010 /PRNewswire/ -- From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.

Under the terms of the new agreement, CellCentric will receive from Takeda Pharmaceutical Company Limited an upfront payment and pre-clinical and clinical milestones, in addition to royalties. Based on the royalties and milestones defined, the overall deal could be worth in excess of $200m to CellCentric over the course of the agreement.

This is a pioneering deal for the emerging area of epigenetics, demonstrating the commercial interest in novel epigenetic targets beyond HDACs (histone deacetylases) and DNMTs (DNA methyltransferases ). Therapeutic research will be initiated by Takeda's Research Group. Development of molecules stemming from this agreement will be completed by Millennium: The Takeda Oncology Company, which is responsible for Takeda's global oncology development strategy.

Many diseases including cancer involve a loss of cell fate control. In many cases this is associated with aberrant epigenetic changes to chromatin: dynamic modifications of DNA and its associated proteins, including histones. These epigenetic alterations are caused by a range of enzymes. Initial therapeutic interest has been focused on inhibiting HDAC and DNMTs. It has become increasingly clear that there are many other key epigenetic related enzymes that can be targeted and which may offer greater specificity of action. These include histone methyltransferases, demethylases and ubiquitin-related enzymes.

CellCentric has an innovation platform built upon relationships with over 30 world leading research labs in epigenetics. The company has identified and prioritised multiple next generation targets and runs a series of active drug discovery programmes from its centre in Cambridge, UK. As programmes move forward, CellCentric is able to gain continued benefit and support from multiple Principal Investigators within its network.

With an extensive portfolio and rich pipeline, CellCentric's strategy is to develop some target programmes through licences and collaborations with Pharmaceutical companies while retaining other programmes for development itself.

Dr Hiroyuki Odaka, General Manager of the Pharmaceutical Research Division of Takeda said "Epigenetics is an important area for novel oncology therapeutics. This new agreement demonstrates our commitment to researching and pioneering the best ways to treat cancer."

Dr Will West, CEO of CellCentric added "This licence is a strong endorsement of the way we are approaching innovation in epigenetics. This is an area that is no longer seen as just interesting, but as a necessity for pharmaceutical companies growing their armoury for tackling intractable diseases such as cancer".

Notes:

CellCentric is a biotechnology company focused on epigenetics. Formed in 2004, it works with over 30 academic labs worldwide to identify, patent and commercialise product opportunities. CellCentric currently has 7 novel target discovery programmes ongoing, focused on cancer, as well as multiple projects related to reprogramming and epigenetic tools. For further details on the company, see: http://www.cellcentric.com.

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website http://www.takeda.com.

SOURCE CellCentric Ltd

Back to top
'/>"/>
SOURCE CellCentric Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PSKW & Associates LLC Acquires Triax Media, Licenses Triax to Subsidiary, Centricity Group
2. TenX Biopharma Licenses Zanolimumab From Genmab
3. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
4. Raytheon BBN Technologies Licenses Stereo Digital Mammography Technology to FUJIFILM Corporation
5. SCOLR Pharma, Inc. Licenses Dietary Supplements
6. StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke
7. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
8. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
9. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
10. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
11. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb. 24, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to their ... The Global Empty ... over the next decade to reach approximately $2.9 billion by 2025. ... all the given segments on global as well as regional levels presented ...
(Date:2/24/2017)... HILL, N.C. , Feb. 24, 2017 /PRNewswire/ ... are exploring ways to increase their self-service capabilities ... Health Care Providers (HCPs). New research ... many pharma organizations have developed self-service website portals ... electronically.  This is just one of many findings ...
(Date:2/24/2017)... le 24 février 2017 ITL Limited, ( ASX : ITD ... est ravie d,annoncer les excellents résultats semestriels clos le ... correspondante. Une présentation complète « Résultats et mise à jour ... ici . Faits marquants ... 2015 : 1,04 million $ ; en hausse de 104 %) ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been paid to the ... dependent on opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from ... in fatal overdoses in male populations.(1) , The proportion of women using illicit drugs ...
(Date:2/27/2017)... Shenzhen, China (PRWEB) , ... February 26, 2017 , ... ... , This pioneer sound and video system brings songs, movies, TV shows and much ... 3D sound offers clear, high-definition sound. An immersive view of 1280 x 720 provides ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based in ... Palo Alto, is proud to announce an important upgrade to its geographic information pages, ... care close to home, and by having city-specific pages, NuevaCare is answering that information ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data ... to a study released today at the 1st Pan American Parkinson’s and Movement ... to be effective in improving cognitive function in PD patients. This study, led ...
Breaking Medicine News(10 mins):